Information about Medications Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
Safety Information about Medications for ADHD
- FDA Drug Safety Communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD
- FDA Drug Safety Communication: FDA warns of rare risk of long-lasting erections in males taking methylphenidate ADHD medications and has approved label changes
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults
- FDA Drug Safety Podcast for Healthcare Professionals: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- FDA Drug Safety Podcast for Healthcare Professionals: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults
- Comunicado de la FDA sobre la seguridad de los medicamentos: Informe actualizado sobre la seguridad de medicamentos usados para el tratamiento del Trastorno de Déficit de Atención con Hiperactividad (ADHD por sus siglas en inglés) en niños y adultos jóvenes
- Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
- FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides
- Adderall and Adderall XR (amphetamines) Information
- Atomoxetine (marketed as Strattera) Information
- Information for Healthcare Professionals: Cylert (pemoline) Tablets and Chewable Tablets